The Stock Exchange of Hong Kong Limited has taken disciplinary action against two former directors of China Health Technology Group Holding Company Limited, previously known as China Bozza Development Holdings Limited (Stock Code: 1069). The Exchange issued a Director Unsuitability Statement and censured Mr. Wang Yue, a former executive director, and Ms. Tian Guangmei, a former independent non-executive director, deeming them unsuitable for any director or senior management roles within the company or its subsidiaries. This action follows their involvement in the approval and extension of loans totaling HK$138.3 million between 2015 and 2019, alongside their failure to cooperate with the Exchange's investigation. The disciplinary measures are solely applicable to the two individuals and not to the company or its other directors. The announcement was made on May 28, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.